Loading …

One-carbon therapeutics AB is developing first-in-class MTHFD1/2 inhibitors of one-carbon metabolism, representing a novel way of attacking the DNA damage response (DDR) and targeting cancer.
Annual Revenue$1M to $5M
Estimated OwnershipPrivateBuilt from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Matching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.